These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28964482)

  • 41. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease.
    Gross TG
    Recent Results Cancer Res; 2002; 159():96-103. PubMed ID: 11785850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update.
    Hertig A; Zuckermann A
    Transpl Immunol; 2015 Jun; 32(3):179-87. PubMed ID: 25936966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Post transplant lymphoprolipherative disorder (PTLD) in patients after kidney transplantation--clinical manifestation, treatment and prognosis].
    Pałka K; Ignacak E; Sułowicz W
    Przegl Lek; 2012; 69(9):675-9. PubMed ID: 23401988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutaneous involvement of polymorphic post-transplant lymphoproliferative disorder in a child after liver transplantation.
    Chen KY; Lin CY; Kuo TT; Shih LY; Chang CH; Chen WT; Yang CY
    Pediatr Dermatol; 2019 Sep; 36(5):681-685. PubMed ID: 31215060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.
    Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B
    J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.
    Montes de Jesus FM; Kwee TC; Nijland M; Kahle XU; Huls G; Dierckx RAJO; van Meerten T; Gheysens O; Dierickx D; Vergote V; Noordzij W; Glaudemans AWJM
    Crit Rev Oncol Hematol; 2018 Dec; 132():27-38. PubMed ID: 30447925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.
    Haruki K; Shiba H; Shimada J; Okui N; Iida T; Yanaga K
    Clin J Gastroenterol; 2017 Feb; 10(1):47-51. PubMed ID: 27796825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series.
    Montanari F; Radeski D; Seshan V; Alobeid B; Bhagat G; O'Connor OA
    Br J Haematol; 2015 Nov; 171(4):491-500. PubMed ID: 26250758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M
    Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
    Kline K; Chen W; Kallen ME; Koka R; Omili D; Fan X; Iraguha T; Gebru E; Dishanthan N; Baker JM; Dietze KA; Yared JA; Hankey K; Dahiya S; Niederhaus SV; Dunleavy K; Hardy NM; Luetkens T; Rapoport AP; Atanackovic D
    Hum Vaccin Immunother; 2023 Aug; 19(2):2216116. PubMed ID: 37278257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study.
    Lo RC; Chan SC; Chan KL; Chiang AK; Lo CM; Ng IO
    J Clin Pathol; 2013 May; 66(5):392-8. PubMed ID: 23423516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?
    Mucha K; Foroncewicz B; Ziarkiewicz-Wróblewska B; Krawczyk M; Lerut J; Paczek L
    Nephrol Dial Transplant; 2010 Jul; 25(7):2089-98. PubMed ID: 20576725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.
    Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
    Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders.
    Borrows R; Scheer A; Cockwell P; Braun F; Anagnostopoulos I; Riess H; Zimmermann H; Trappe RU
    Ann Hematol; 2019 Mar; 98(3):625-632. PubMed ID: 30680506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.